Skip to main content

Table 2 Therapeutic regimens, survival outcomes and toxicities in eligible studies

From: The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis

StudyInduction chemotherapyRadiotherapyConcurrent chemotherapyIC + CCRT|CCRT
OS rateFFS rateDMFS rateLRFS rateORRGrade ≥ 3 AE rate
Fountzilas 2012 [8]Epi 75 mg/m2, Pac 175 mg/m2 and DDP 75 mg/m2 every 21 days for 3 cycles2D-CRT, 3D-CRTDDP 40 mg/m2 every week3-year: 66.6%|71.8%3-year: 64.5%|63.5%FEFE83%|85%FE
Tan 2015 [9]Gem 1000 mg/m2, CBP area under the concentration-time-curve 2.5, and Pac 70 mg/m2 (day 1 and 8) every 21 days for 3 cycles2D-CRT, IMRTDDP 40 mg/m2 every week3-year: 94.3%|92.3%3-year: 74.9%|67.4%3-year: 83.8%|79.9%FEFE52%|37%b
Sun/Li 2016/2019 [10] [11]Doc 60 mg/m2, DDP 60 mg/m2 and 5-FU 600 mg/m2 every 21 days for 3 cyclesIMRTDDP 100 mg/m2 every 21 days for 3 cycles3-year: 92.1%|86.2%;
5-year: 85.6%|77.7%
3-year: 80.1%|72.0%;
5-year: 77.4%|66.4%
3-year: 88.8%|82.0%;
5-year: 88.0%|79.8%b
3-year: 91.7%|87.4%;
5-year: 90.7%|83.8%b
98.8%|100%72.8%|53.8%
Cao/Yang 2017/2019 [12] [13]DDP 80 mg/m2 and 5-FU 800 mg/m2 (day 1–5) every 21 days for 2 cycles2D-CRT, IMRTDDP 80 mg/m2 every 21 days for 3 cycles3-year: 88.2%|88.5%; 5-year: 80.8%|76.8%b3-year: 82.0%|74.1%; 5-year: 73.4%|63.1%b3-year: 86.0%|82.0%; 5-year: 82.8%|73.1%b3-year: 94.3%|90.8%; 5-year: 87.9%|85.0%98.7%|99.2%66.3%|49.1%ab
Frikha 2018 [14]Doc 75 mg/m2, DDP 75 mg/m2 and 5-FU 750 mg/m2/day day (1–5) every 21 days for 3 cyclesIMRT, non-IMRTDDP 40 mg/m2 every week3-year: 86.3%|68.9%3-year: 73.9%|57.2%FEFEFEFE
Hong 2018 [15]Mit 8 mg/m2, Epi 60 mg/m2, and DDP 60 mg/m2 on day 1, 5-FU 450 mg/m2 and Leu 30 mg/m2 on day 83D-CRT, IMRTDDP 30 mg/m2 every week5-year: 72.0%|67.9%5-year: 61.1%|50.0%5-year: 76.2%|70.8%5-year: 79.9%|70.0%95.3%|92.5%FE
Zhang 2019 [16]Gem 1 g/m2 (day 1 and 8) and DDP 80 mg/m2 every 21 days for 3 cyclesIMRTDDP 100 mg/m2 every 21 days for 3 cycles3-year: 94.6%|90.3%3-year: 85.3%|76.5%3-year: 91.1%|84.4%3-year: 91.8%|91.0%97.9%|98.7%75.7%|55.7%
  1. epirubicin: Epi; paclitaxel: Pac; cisplatin: DDP; gemcitabine: Gem; carboplatin: CBP; docetaxel: Doc; 5-fluorouracil: 5-FU; mitomycin: Mit; leucovorin: Leu; 2D/2D-CRT: 2/3-dimensional conformal radiotherapy; IMRT intensity modulated radiotherapy; OS overall survival; FFS failure-free survival; DMFS distant metastasis-free survival; LRFS locoregional relapse-free survival; ORR objective response rate; AE adverse event; FE fail to extract
  2. a AE during concurrent chemotherapy
  3. b means statistically significant